Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ACE | P12821 | 4/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191624 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL14032460 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL17679171 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL16743957 | 0.86 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL13126117 | 0.86 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL26178695 | 0.86 | HTR2A (0.59) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL4319903 | 0.86 | FFAR4 (0.51) | MMEACECPA1ACE2 | |
| SCHEMBL8102861 | 0.85 | HTR2A (0.57) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL13209550 | 0.85 | HTR2A (0.62) | HTR2AHTR2CHTR2BMMEACE | |
| SCHEMBL20067117 | 0.85 | HTR2A (0.57) | HTR2AHTR2CHTR2BMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248997-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR COVID-19 | Hiroshima University (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-10280238-B2 | Transition metal compound, catalyst composition comprising same, and method for producing olefin polymer using same | LG CHEM, LTD. (KR) | 2019-05-07 | — | — | US | disclosed |
| US-20180105616-A1 | TRANSITION METAL COMPOUND, CATALYST COMPOSITION COMPRISING SAME, AND METHOD FOR PRODUCING OLEFIN POLYMER USING SAME | LG CHEM, LTD. (KR) | 2018-04-19 | — | — | US | disclosed |
| US-20180105616-A1 | TRANSITION METAL COMPOUND, CATALYST COMPOSITION COMPRISING SAME, AND METHOD FOR PRODUCING OLEFIN POLYMER USING SAME | LG CHEM, LTD. (KR) | 2018-04-19 | — | — | US | disclosed |
| US-8980581-B2 | Site-specific incorporation of amino acids into molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140045261-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | HTR2A 4707/4885HTR2C 4758/4885HTR2B 4778/4885 |
| US-10280238-B2 | Transition metal compound, catalyst composition comprising same, and method for producing olefin polymer using same | NOTUM, SOAT2, SOAT1 | HTR2A 4861/4885HTR2C 4843/4885HTR2B 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.